Industry News

Zydus Lifesciences Ltd., an innovation-driven global life sciences announced that it has acquired rights to market MonoFerric  (iron isomaltoside) injections in India and Nepal from Denmark based Pharmacosmos A/S. MonoFerric , iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron (up to 20 mg/kg bodyweight) developed to reduce the number of infusions required to achieve iron correction with an excellent safety profile.

Indian Pharmaceutical Alliance (IPA) gives clean chit to Micro Labs, Dolo maker, against a case on Rs. 1,000 crores in freebies to doctors, and states that the company is following the processes as per the Uniform Code of Pharmaceutical Marketing Practices, UCPMP, guidelines.

Novartis announced the results from two pivotal, Phase III studies, in which Cosentyx (secukinumab) demonstrated rapid and sustained relief from the common clinical signs and symptoms of moderate-to-severe hidradenitis suppurativa (HS) with a favorable safety profile.

The data were presented as a late-breaking abstract at the 31st European Academy of Dermatology and Venereology (EADV) Congress.

​U.S. Food and Drug Administration (FDA) is alerting health care providers about potential clip lock malfunctions with MitraClip Delivery Systems manufactured by Abbott.

An increased rate of reports of clip lock malfunctions has been observed before and after clip deployment. These events appear to occur in approximately 1.3% of MitraClip procedures and have been observed with all device models, said Abbott.

Cipla and Dr Reddys Lab receives FDA nod for marketing of generic version of REVLIMID (lenalidomide) Capsules. Both companies have received final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules.

With this volume-limited launch, Dr. Reddy’s Lab is eligible for first-to- market, 180 days of generic drug exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths.

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalisation for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression with and without type-2 diabetes (T2D).

Lupin and DKSH have signed an exclusive license and supply agreement to commercialize five of Alvotechs proposed biosimilars in the Philippines. The biosimilars planned under this agreement include biosimilar Prolia, Xgeva, Simponi, and Eylea as well as two undisclosed proposed biosimilars for immunology and oncology.

GE Healthcare, a leading global medical technology, diagnostics and digital solutions innovator, has announced the launch of its first Made in India, AI-powered Cath lab - Optima IGS 320 to advance cardiac care in India.

​​​​The overall Indian pharmaceutical market grown around 12.1 percent by value and 4.8 percent by volume in month of August as per the market research firm AWACS.

Almost all the therapy areas have shown a robust double-digit growth or in case of units the growth may be single digit due to NLEM permission to hike price come into the picture and number of companies have shown a good price driven growth for the month of August.